Clinical Trial: NCT03853616
MB-CART19.1 r/r CD19+ B-cell Malignancies (BCM)
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 1| Lead Sponsor: | Miltenyi Biomedicine GmbH |
| Information Provided By: | Miltenyi Biomedicine GmbH |
| Last Update Posted: | 2026-10-09 |
Study Overview
Brief Summary
This is a phase l multi-centric, single arm, prospective open, dose-escalation study in patients with relapsed or refractory CD19-positive B cell malignancies (ALL, NHL, CLL). The trial will include adult and pediatric patients. In total approximately 48 patients will be included in the trial. There will be three individual cohorts, defined by disease biology: pediatric ALL and aggressive pediatric NHL (Cohort 1), adult ALL (Cohort 2) and adult NHL/CLL (Cohort 3).
Official Title
Conditions
Intervention / Treatment
- Biological: MB-CART19.1
Other Study ID Numbers
- M-2017-322
- 2017-002848-32
- 2017
Start Date (Actual)
Primary Completion Date (Estimated)
Study Completion Date (Estimated)
Enrollment (Estimated)
Study Type
Phase
| Lead Sponsor: | Miltenyi Biomedicine GmbH |
| Information Provided By: | Miltenyi Biomedicine GmbH |
| Last Update Posted: | 2026-10-09 |
Study Overview
Brief Summary
This is a phase l multi-centric, single arm, prospective open, dose-escalation study in patients with relapsed or refractory CD19-positive B cell malignancies (ALL, NHL, CLL). The trial will include adult and pediatric patients. In total approximately 48 patients will be included in the trial. There will be three individual cohorts, defined by disease biology: pediatric ALL and aggressive pediatric NHL (Cohort 1), adult ALL (Cohort 2) and adult NHL/CLL (Cohort 3).
Official Title
Conditions
Intervention / Treatment
- Biological: MB-CART19.1
Other Study ID Numbers
- M-2017-322
- 2017-002848-32
- 2017